Copyright
©The Author(s) 2022.
World J Clin Cases. Mar 16, 2022; 10(8): 2393-2403
Published online Mar 16, 2022. doi: 10.12998/wjcc.v10.i8.2393
Published online Mar 16, 2022. doi: 10.12998/wjcc.v10.i8.2393
Figure 3 Immunohistochemical indicators in patients with pancreatic adenocarcinoma.
CD34-MVD, CD105-MVD, VEGF, and (α-SMA)-MVD in patients with grade III pancreatic adenocarcinoma (right) were compared with CD34-MVD, CD105-MVD, VEGF, and (α-SMA)-MVD in patients with grade I pancreatic adenocarcinoma (left). Magnification × 400.
- Citation: Liu W, Yin B, Liang ZH, Yu Y, Lu N. Computed tomography perfusion imaging evaluation of angiogenesis in patients with pancreatic adenocarcinoma. World J Clin Cases 2022; 10(8): 2393-2403
- URL: https://www.wjgnet.com/2307-8960/full/v10/i8/2393.htm
- DOI: https://dx.doi.org/10.12998/wjcc.v10.i8.2393